Pair Name	Gambogic Acid, MG132
Disease Info	[ICD-11: 2C25.Z]	Lung cancer		Investigative
Gene Regulation	Up-regulation	Cleavage	PARP1	hsa142
In Vitro Model	K-562	Blast phase chronic myelogenous leukemia	Homo sapiens (Human)	CVCL_0004
	H-22	Peripheral primitive neuroectodermal tumor	Homo sapiens (Human)	CVCL_1E32
In Vivo Model	The findings presented in this study demonstrate that natural product gambogic acid is a valuable candidate to be used in combination with proteasome inhibitors, thus representing a compelling anticancer strategy.
Result	The combination of natural product gambogic acid and the proteasome inhibitor MG132 or MG262 results in a synergistic inhibitory effect on growth of malignant cells and tumors in allograft animal models and there was no apparent systemic toxicity observed in the animals treated with the combination